<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="urofacial" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">urofacial</book-part-id>
      <title-group>
        <title>Urofacial Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonym: Ochoa Syndrome</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Newman</surname>
            <given-names>William G</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>william.newman@manchester.ac.uk</email>
          <aff>Manchester Centre for Genomic Medicine<break/>University of Manchester and Central Manchester University Hospitals NHS Foundation Trust<break/>Manchester, United Kingdom</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Woolf</surname>
            <given-names>Adrian S</given-names>
          </name>
          <degrees>MD</degrees>
          <email>adrian.woolf@manchester.ac.uk</email>
          <aff>Centre for Paediatrics and Child Health<break/>University of Manchester and Central Manchester University Hospitals NHS Foundation Trust<break/>Manchester, United Kingdom</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stuart</surname>
            <given-names>Helen M</given-names>
          </name>
          <degrees>MD</degrees>
          <email>helen.stuart@manchester.ac.uk</email>
          <aff>Manchester Centre for Genomic Medicine<break/>University of Manchester and Central Manchester University Hospitals NHS Foundation Trust<break/>Manchester, United Kingdom</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2013-08-22" date-type="created">
          <day>22</day>
          <month>8</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="ucd-overview" document-type="chapter">Urea Cycle Disorders Overview</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="usher1" document-type="chapter">Usher Syndrome Type I</related-object>
      <abstract id="urofacial.Summary">
        <title>Summary</title>
        <sec>
          <title>Clincial characteristics</title>
          <p>Urofacial syndrome (UFS) is characterized by prenatal or infantile onset of urinary bladder voiding dysfunction, abnormal facial movement with expression (resulting from abnormal co-contraction of the corners of the mouth and eyes), and often bowel dysfunction (constipation and/or encopresis). Bladder voiding dysfunction increases the risk for urinary incontinence, megacystis, vesicoureteric reflux, hydroureteronephrosis, urosepsis, and progressive renal impairment.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of UFS is based on investigations of the urinary tract that reveal characteristic urinary tract abnormalities and physical examination that reveals characteristic facial movement with expression. UFS is a heterogeneous condition resulting from biallelic pathogenic variants in either <italic toggle="yes">HPSE2</italic> or <italic toggle="yes">LRIG2</italic>. In some instances no pathogenic change has been identified.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Rapid and complete treatment of urinary tract infections and routine treatment of urosepsis. For urinary incontinence and bladder dysfunction: use of anticholinergic and &#x003b1;<sub>1</sub>-adrenergic blockers; intermittent catheterization or vesicostomy; surgical management of hydroureteronephrosis and bladder augmentation should be considered. Management of chronic kidney disease (CKD) and end-stage renal disease (ESRD) relies on the standard optimal options.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitor for evidence of urinary tract features including vesicoureteric reflux (VUR) and hydroureteronephrosis. Renal function should be monitored at intervals determined by urinary tract features at presentation and their subsequent progression.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Nephrotoxic substances.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> It is appropriate to examine sibs of an affected individual as soon as possible after birth to determine if facial and/or urinary tract manifestations of UFS are present to allow prompt evaluation of the urinary tract and renal function and prompt initiation of necessary treatment.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Although no guidelines for prenatal management of UFS exist, it seems appropriate to perform ultrasound examination of pregnancies at risk to determine if urinary tract involvement of UFS is present, as this may influence the timing and/or location of delivery (e.g., in a tertiary medical center that could manage renal/urinary complications immediately after birth).</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>UFS is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing of pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="urofacial.Diagnosis">
        <title>Diagnosis</title>
        <p>No formal diagnostic criteria for urofacial syndrome (UFS) have been published.</p>
        <p><bold>The clinical diagnosis of UFS is typically established by the presence of the two main features</bold> involving the urinary bladder and face [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Urinary bladder dysfunction</bold> (also termed non-neurogenic neurogenic voiding dysfunction, occult or subclinical neuropathic bladder) with detrusor over-activity and detrusor sphincter dyssynergia [<xref ref-type="bibr" rid="urofacial.REF.feldman.2006.139">Feldman &#x00026; Bauer 2006</xref>]. Affected individuals are at risk for urinary incontinence, urosepsis, and progressive renal impairment [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>]. Urinary tract features have been present in all but two of over 150 reported individuals [<xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>A characteristic abnormality of facial movement with expression,</bold> resulting from abnormal co-contraction of the corners of the mouth and eyes, which is most obvious during smiling or laughing and often described as a &#x02018;grimace&#x02019; [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.ganesan.2011.507">Ganesan &#x00026; Thomas 2011</xref>]. Typical facial expressions have been present in all but one individual (who was diagnosed due to classic features in a relative) [<xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>].</p>
          </list-item>
        </list>
        <p><bold>A third feature, bowel dysfunction</bold>, including constipation, is reported in about 66% and encopresis in 33% of affected individuals [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>].</p>
        <p>Of note, UFS is likely to be under-diagnosed due to (1) the overlap of the urinary tract features of UFS with other disorders of the lower urinary tract and (2) lack of recognition of the characteristic facial expression.</p>
        <p><bold>To confirm/establish the diagnosis of urofacial syndrome in a proband</bold> requires:</p>
        <list list-type="bullet">
          <list-item>
            <p>Investigations of the urinary tract that reveal characteristic abnormalities:</p>
            <list list-type="bullet">
              <list-item>
                <p>Postnatal imaging of the bladder typically shows muscular thickening and trabeculation, but may also be normal [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.derbent.2009.589">Derbent et al 2009</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>].</p>
              </list-item>
              <list-item>
                <p>Hydroureteronephrosis is common [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>].</p>
              </list-item>
              <list-item>
                <p>Micturating cystourethrogram may reveal vesicoureteric reflux [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>]; intra-urethral anatomic lesions are not observed.</p>
              </list-item>
              <list-item>
                <p>Cystoscopy, if performed, reveals no urethral lesions.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Molecular genetic testing to identify biallelic pathogenic variants in one of the two genes &#x02013; <italic toggle="yes">HPSE2</italic> and <italic toggle="yes">LRIG2</italic> &#x02013; in which mutation is currently known to cause UFS (see <xref ref-type="table" rid="urofacial.T.summary_of_molecular_genetic">Table 1</xref>)</p>
          </list-item>
        </list>
        <table-wrap id="urofacial.T.summary_of_molecular_genetic" position="anchor" orientation="portrait">
          <label>Table 1. </label>
          <caption>
            <p>Summary of Molecular Genetic Testing Used in Urofacial Syndrome</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                <th id="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Proportion of UFS Attributed to Mutation of This Gene to Date&#x000a0;<sup>2</sup></th>
                <th id="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                <th id="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>3</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">HPSE2</italic>
                </td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">9/14</td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
              </tr>
              <tr>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Exonic or whole-gene deletions</td>
              </tr>
              <tr>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">LRIG2</italic>
                </td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">3/14</td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
              </tr>
              <tr>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions</td>
              </tr>
              <tr>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown</td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2/14</td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                <td headers="hd_h_urofacial.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="urofacial.TF.1.1">
              <label>1. </label>
              <p>See <related-object source-id="gene" document-id="urofacial" object-id="urofacial.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
            </fn>
            <fn id="urofacial.TF.1.2">
              <label>2. </label>
              <p>
                <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al [2013]</xref>
              </p>
            </fn>
            <fn id="urofacial.TF.1.3">
              <label>3. </label>
              <p>See <xref ref-type="sec" rid="urofacial.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
            </fn>
            <fn id="urofacial.TF.1.4">
              <label>4. </label>
              <p>Examples of variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
            </fn>
            <fn id="urofacial.TF.1.5">
              <label>5. </label>
              <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="urofacial.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="urofacial.Clinical_Description">
          <title>Clinical Description</title>
          <p>The main features of urofacial syndrome (UFS) are congenital urinary bladder voiding dysfunction and an abnormality of facial movement with expression which can be observed from birth. Bowel dysfunction is common.</p>
          <p>Significant inter- and intrafamilial phenotypic variability has been observed [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          <p>Urinary tract features are the main reason for presenting to medical attention and the main cause of associated morbidity and mortality.</p>
          <p>UFS is not associated with growth or developmental abnormality other than that attributable to chronic renal disease. Intellect is normal.</p>
          <p><bold>Urinary tract.</bold> Urinary tract features have been present in all but two of over 150 reported individuals [<xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          <p>Antenatal ultrasound examination (if performed) is frequently described as abnormal and is associated with megacystis, hydroureteronephrosis, and renal pelvis dilatation [<xref ref-type="bibr" rid="urofacial.REF.sk_lov_.2006.125">Sk&#x000e1;lov&#x000e1; et al 2006</xref>, <xref ref-type="bibr" rid="urofacial.REF.bacchetta.2010.225">Bacchetta &#x00026; Cochat 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.daly.2010.963">Daly et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          <p>Severe neonatal and infant presentations with urinary tract complications including urinary bladder rupture and sepsis have been reported [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.sk_lov_.2006.125">Sk&#x000e1;lov&#x000e1; et al 2006</xref>].</p>
          <p>More typical presentations of urinary tract features include recurrent urinary sepsis and failure to achieve urinary continence [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>].</p>
          <p>In the Ochoa cohort hydroureteronephrosis was found in 29/50 (58%) of affected individuals [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>], a finding consistent with the range of urinary tract abnormalities in other case reports [<xref ref-type="bibr" rid="urofacial.REF.chauve.2000.10">Chauve et al 2000</xref>, <xref ref-type="bibr" rid="urofacial.REF.garciaminaur.2001.165">Garcia-Minaur et al 2001</xref>, Al Qahtani 2003, <xref ref-type="bibr" rid="urofacial.REF.nicanor.2005.477">Nicanor et al 2005</xref>, <xref ref-type="bibr" rid="urofacial.REF.sk_lov_.2006.125">Sk&#x000e1;lov&#x000e1; et al 2006</xref>, <xref ref-type="bibr" rid="urofacial.REF.derbent.2009.589">Derbent et al 2009</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.daly.2010.963">Daly et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stamatiou.2010.582">Stamatiou &#x00026; Karakos 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.sutay.2010.445">Sutay et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.al_badr.2011.569">Al Badr et al 2011</xref>, <xref ref-type="bibr" rid="urofacial.REF.mahmood.2012.88">Mahmood et al 2012</xref>, <xref ref-type="bibr" rid="urofacial.REF.akl.2012.346">Akl &#x00026; Al Momany 2012</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          <p><xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa [2004]</xref> identified vesicoureteric reflux in 32/50 (64%); reflux was bilateral in 18 (36%).</p>
          <p>The associated renal parenchymal damage with early impairment of renal function and progression to end-stage renal disease (ESRD) causes substantial morbidity and mortality [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.sk_lov_.2006.125">Sk&#x000e1;lov&#x000e1; et al 2006</xref>, <xref ref-type="bibr" rid="urofacial.REF.sutay.2010.445">Sutay et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.mahmood.2012.88">Mahmood et al 2012</xref>]. The proportion of individuals who develop renal impairment is unknown, but likely to be significant [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1987.661">Ochoa &#x00026; Gorlin 1987</xref>, <xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>].</p>
          <p><bold>Facial expression.</bold> The most prominent facial feature, abnormal co-contraction of the corners of the mouth and eyes, is most obvious during smiling or laughing [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.ganesan.2011.507">Ganesan &#x00026; Thomas 2011</xref>] and can be socially debilitating.</p>
          <p>Symmetric partial facial paresis in the distribution of the facial nerve has been noted; however, the proportion of individuals in whom weakness is a significant feature is unknown [<xref ref-type="bibr" rid="urofacial.REF.garciaminaur.2001.165">Garcia-Minaur et al 2001</xref>; Author, personal observation].</p>
          <p>Abnormal facial movement with crying has been observed as early as the neonatal period [<xref ref-type="bibr" rid="urofacial.REF.ochoa.1992.580">Ochoa 1992</xref>, <xref ref-type="bibr" rid="urofacial.REF.sk_lov_.2006.125">Sk&#x000e1;lov&#x000e1; et al 2006</xref>].</p>
          <p>Typical facial expressions have been present in all but one affected individual (who was diagnosed due to classic features in a relative) [<xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>].</p>
          <p><bold>Gastrointestinal tract.</bold> Constipation is reported in about 66% of affected individuals; encopresis is present in 33% [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>].</p>
          <p>Fecal retention in the neonatal period has been noted once [<xref ref-type="bibr" rid="urofacial.REF.nicanor.2005.477">Nicanor et al 2005</xref>].</p>
          <p>Rectal prolapse has also been reported once in association with severe constipation [<xref ref-type="bibr" rid="urofacial.REF.al_badr.2011.569">Al Badr et al 2011</xref>].</p>
          <p>
            <bold>Other features</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Early descriptions of UFS reported individuals with central nervous system abnormalities including spina bifida occulta, occipital meningocele and hydrocephalus due to stenosis of the aqueduct of Sylvius; however, these are most likely chance associations [<xref ref-type="bibr" rid="urofacial.REF.elejalde.1979.97">Elejalde 1979</xref>, <xref ref-type="bibr" rid="urofacial.REF.teebi.1991.199">Teebi &#x00026; Hassoon 1991</xref>].</p>
            </list-item>
            <list-item>
              <p>MRI of the central nervous system (CNS) &#x02013; performed because the urinary tract features mimic those associated with CNS dysfunction &#x02013; is typically normal [<xref ref-type="bibr" rid="urofacial.REF.nicanor.2005.477">Nicanor et al 2005</xref>, <xref ref-type="bibr" rid="urofacial.REF.derbent.2009.589">Derbent et al 2009</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.al_badr.2011.569">Al Badr et al 2011</xref>, <xref ref-type="bibr" rid="urofacial.REF.akl.2012.346">Akl &#x00026; Al Momany 2012</xref>]. UFS is most likely to represent an abnormality of peripheral rather than central nervous system development, although affected individuals do not typically show any other features of neurologic dysfunction.</p>
            </list-item>
            <list-item>
              <p>An affected individual has been described with asymptomatic Wolff-Parkinson-White syndrome (abnormal development of the cardiac conduction system) [<xref ref-type="bibr" rid="urofacial.REF.garciaminaur.2001.165">Garcia-Minaur et al 2001</xref>] and another with symptomatic postural orthostatic tachycardia [<xref ref-type="bibr" rid="urofacial.REF.al_badr.2011.569">Al Badr et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>In one family all three affected siblings had septated gallbladders and/or gallstones [Al Qahtani 2003].</p>
            </list-item>
          </list>
        </sec>
        <sec id="urofacial.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations have been reported.</p>
        </sec>
        <sec id="urofacial.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance is complete in all series reported to date. However, variable expression from subtle to more striking clinical features is common.</p>
        </sec>
        <sec id="urofacial.Prevalence">
          <title>Prevalence</title>
          <p>UFS is rare. Its prevalence is currently unknown but is likely to be higher in certain populations, e.g., in Colombia due to the presence of a founder mutation and associated consanguinity [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.pang.2010.957">Pang et al 2010</xref>].</p>
        </sec>
      </sec>
      <sec id="urofacial.Genetically_Related_Allelic_Di">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">HPSE2</italic> or <italic toggle="yes">LRIG2</italic>.</p>
      </sec>
      <sec id="urofacial.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The urinary tract features of urofacial syndrome (UFS) overlap with those seen in association with multiple other conditions [<xref ref-type="bibr" rid="urofacial.REF.woolf.2014a.353">Woolf et al 2014a</xref>].</p>
        <list list-type="bullet">
          <list-item>
            <p>Antenatal or congenital megacystis and/or hydronephrosis:</p>
            <list list-type="bullet">
              <list-item>
                <p>Urethral obstruction due to posterior urethral valves or atresia</p>
              </list-item>
              <list-item>
                <p>
                  <related-object link-type="booklink" source-id="gene" document-id="actg2-dis" document-type="chapter">Prune belly syndrome</related-object>
                </p>
              </list-item>
              <list-item>
                <p>Chromosome abnormalities (e.g., megacystis in association with trisomy 21 and 13)</p>
              </list-item>
              <list-item>
                <p>Antenatal urinary tract abnormalities (common minor abnormalities in genetic syndromes)</p>
              </list-item>
              <list-item>
                <p>Lower urinary tract features (may be a prominent feature in some syndromes, including megacystis microcolon intestinal hypoperistalsis syndrome)</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Urinary bladder voiding dysfunction:</p>
            <list list-type="bullet">
              <list-item>
                <p>Secondary to physical obstruction in posterior urethral valves or urethral atresia</p>
              </list-item>
              <list-item>
                <p>Neuropathic bladder, e.g. due to a neurologic lesion such as spina bifida</p>
              </list-item>
              <list-item>
                <p>Voiding dysfunction of unclear etiology, variably termed occult neuropathic bladder, subclinical neuropathic bladder, non-neurogenic neurogenic bladder, and Hinman-Allen syndrome</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Vesicoureteric reflux is common in the general population. It may be familial and is genetically heterogeneous.</p>
          </list-item>
        </list>
      </sec>
      <sec id="urofacial.Management_1">
        <title>Management</title>
        <sec id="urofacial.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with urofacial syndrome (UFS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Urinalysis and urine culture for occult or chronic infection</p>
            </list-item>
            <list-item>
              <p>Assessment of renal function: serum creatinine concentration and/or estimated glomerular filtration rate (eGFR)</p>
            </list-item>
            <list-item>
              <p>Urinary tract ultrasound examination</p>
            </list-item>
            <list-item>
              <p>Micturating cystourethrogram</p>
            </list-item>
            <list-item>
              <p>Uroflowmetry or urodynamic testing</p>
            </list-item>
            <list-item>
              <p>Blood pressure measurement</p>
            </list-item>
            <list-item>
              <p>Assessment of renal parenchymal damage: as indicated by the individual&#x02019;s presentation, dimercaptosuccinic acid (DMSA) isotope scan to visualize functional kidney parenchyma [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>]</p>
            </list-item>
            <list-item>
              <p>Assessment of bowel voiding</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="urofacial.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Urinary tract.</bold> No evidence base exists for treatment of the urinary tract abnormalities of UFS.</p>
          <p>Urinary tract infections warrant rapid and complete treatment. Urosepsis should be treated as per the general population with antibiotic use directed by culture; antibiotic prophylaxis may also be considered.</p>
          <p>Anticholinergic and &#x003b1;<sub>1</sub>-adrenergic blockers have been used in the medical management of urinary incontinence and bladder dysfunction [<xref ref-type="bibr" rid="urofacial.REF.aydogdu.2010.431">Aydogdu et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          <p>Intermittent catheterization or vesicostomy to reduce residual urine volumes and achieve continence with a reduced risk of infections have been used.</p>
          <p>Surgical management of hydroureteronephrosis and bladder augmentation to slow progression of renal impairment have been used; their efficacy is not known [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          <p>Early recognition of renal impairment should initiate intensive management to prevent or slow progression. Renal impairment and hypertension are managed as per clinical status. Successful renal transplantation has been reported [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>].</p>
          <p><bold>Bowel.</bold> Constipation is managed as for the general population.</p>
        </sec>
        <sec id="urofacial.Surveillance">
          <title>Surveillance</title>
          <p>Monitor for evidence of urinary tract features including vesicoureteric reflux (VUR) and hydroureteronephrosis. Renal function should be monitored at intervals determined by urinary tract features at presentation and their subsequent progression.</p>
        </sec>
        <sec id="urofacial.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Nephrotoxic substances contraindicated in individuals with renal impairment should be avoided if possible.</p>
        </sec>
        <sec id="urofacial.Evaluation_of_Relatives_at_Ris">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to examine sibs of an affected individual as soon as possible after birth to determine if facial and/or urinary tract manifestations of UFS are present to allow prompt evaluation of the urinary tract and renal function and prompt initiation of necessary treatment.</p>
          <p>See <xref ref-type="sec" rid="urofacial.Related_Genetic_Counseling_Iss">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="urofacial.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Although no guidelines for prenatal management of UFS exist, it seems appropriate to perform ultrasound examination of pregnancies at risk to determine if urinary tract involvement of UFS is present, as it may influence the timing and/or location of delivery (e.g., in a tertiary medical center that could manage renal/urinary complications immediately after birth).</p>
        </sec>
        <sec id="urofacial.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="urofacial.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="urofacial.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Urofacial syndrome (UFS) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="urofacial.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutant allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with <italic toggle="yes">HPSE2</italic>-related or <italic toggle="yes">LRIG2</italic>-related UFS are obligate heterozygotes for an <italic toggle="yes">HPSE2</italic> or <italic toggle="yes">LRIG2</italic> pathogenic variant, respectively (i.e., all offspring are carriers of a pathogenic variant inherited from their parent).</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="urofacial.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the pathogenic variants in the family.</p>
        </sec>
        <sec id="urofacial.Related_Genetic_Counseling_Iss">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="urofacial.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling&#x000a0;(including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="urofacial.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>Molecular genetic testing.</bold> If the pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk is possible either through a clinical laboratory or a laboratory offering custom prenatal testing.</p>
          <p><bold>Fetal ultrasonography.</bold> In families at risk of having an affected child, prenatal ultrasound of the urinary tract may show megacystis, hydroureteronephrosis, or renal pelvis dilatation in an affected pregnancy. These features are not specific for UFS.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="urofacial.Resources">
        <title>Resources</title>
      </sec>
      <sec id="urofacial.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="urofacial.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The molecular pathogenesis of urofacial syndrome (UFS) is not currently understood. It had previously been speculated that the features of UFS could result from a central nervous system abnormality [<xref ref-type="bibr" rid="urofacial.REF.ochoa.2004.6">Ochoa 2004</xref>]. However, it is now considered more likely that UFS represents an abnormality of peripheral neurodevelopment or function [<xref ref-type="bibr" rid="urofacial.REF.ganesan.2011.507">Ganesan &#x00026; Thomas 2011</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>, <xref ref-type="bibr" rid="urofacial.REF.woolf.2014b.513">Woolf et al 2014b</xref>].</p>
          <p>Both <italic toggle="yes">HPSE2</italic> and its encoded protein heparanase 2 and <italic toggle="yes">LRIG2</italic> and its encoded protein the leucine-rich repeats and immunoglobulin-like domains 2 (LRIG2) are expressed and localize to the peripheral nervous system, including the developing nerves of the fetal bladder [<xref ref-type="bibr" rid="urofacial.REF.mckenzie.2000.1170">McKenzie et al 2000</xref>, <xref ref-type="bibr" rid="urofacial.REF.guo.2004.157">Guo et al 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.homma.2009.1">Homma et al 2009</xref>, <xref ref-type="bibr" rid="urofacial.REF.daly.2010.963">Daly et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
          <p>While the functions of heparanase 2 and LRIG2 are not fully understood, current knowledge suggests that they have a role in regulating growth factor signaling [<xref ref-type="bibr" rid="urofacial.REF.hedman.2007.676">Hedman &#x00026; Henriksson 2007</xref>, <xref ref-type="bibr" rid="urofacial.REF.fux.2009.511">Fux et al 2009</xref>, <xref ref-type="bibr" rid="urofacial.REF.levyadam.2010.28010">Levy-Adam et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.pang.2010.957">Pang et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.cui.2011.273">Cui et al 2011</xref>].</p>
          <sec id="urofacial.HPSE2">
            <title>
              <italic toggle="yes">HPSE2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">HPSE2</italic> is expressed as three protein-coding mRNA transcripts resulting from alternate splicing of 12 exons [<xref ref-type="bibr" rid="urofacial.REF.mckenzie.2000.1170">McKenzie et al 2000</xref>]. The variant transcript encoding the longest protein isoforms is <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_021828.4">NM_021828.4</ext-link>.</p>
            <p><bold>Benign allelic variants.</bold> Many allelic variants recognized in this gene are considered to be non-pathogenic. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="urofacial" object-id="urofacial.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> Pathogenic changes resulting in presumed loss of function include frameshift and nonsense variants, exonic deletions, and, in one instance, a pathogenic missense variant [<xref ref-type="bibr" rid="urofacial.REF.daly.2010.963">Daly et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.pang.2010.957">Pang et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.al_badr.2011.569">Al Badr et al 2011</xref>, <xref ref-type="bibr" rid="urofacial.REF.mahmood.2012.88">Mahmood et al 2012</xref>].</p>
            <p>Pathogenic variants have been found throughout <italic toggle="yes">HPSE2</italic> with no mutational hot-spots.</p>
            <p>The founder mutation c.1516C&#x0003e;T in exon 11 has been identified in the Colombian population [<xref ref-type="bibr" rid="urofacial.REF.pang.2010.957">Pang et al 2010</xref>].</p>
            <p>The pathogenic variant c.1465_1466delAA in exon 10 has been found in individuals of Irish ancestry [<xref ref-type="bibr" rid="urofacial.REF.daly.2010.963">Daly et al 2010</xref>, <xref ref-type="bibr" rid="urofacial.REF.pang.2010.957">Pang et al 2010</xref>].</p>
            <table-wrap id="urofacial.T.hpse2_pathogenic_variants_di" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p><italic toggle="yes">HPSE2</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                    <th id="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1465_1466delAA</td>
                    <td headers="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn489ProfsTer126</td>
                    <td headers="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_021828.4">NM_021828.4</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_068600.4">NP_068600.4</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1516C&#x0003e;T</td>
                    <td headers="hd_h_urofacial.T.hpse2_pathogenic_variants_di_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg506Ter</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">HPSE2</italic> encodes heparanase 2 and has three isoforms of 592 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_068600.4">NP_068600.4</ext-link>), 534 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001159716.1">NP_001159716.1</ext-link>) and 480 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001159717.1">NP_001159717.1</ext-link>) amino acids. Heparanase 2 shows 35% identity with heparanase 1, which is highest over their shared heparan sulfate binding domain [<xref ref-type="bibr" rid="urofacial.REF.mckenzie.2000.1170">McKenzie et al 2000</xref>].</p>
            <p><bold>Abnormal gene product.</bold> The mechanism by which loss of heparanase 2 results in disease is currently unknown.</p>
          </sec>
          <sec id="urofacial.LRIG2">
            <title>
              <italic toggle="yes">LRIG2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">LRIG2</italic> is expressed as five mRNA variants from alternative splicing of 18 exons [<xref ref-type="bibr" rid="urofacial.REF.holmlund.2004.35">Holmlund et al 2004</xref>]. One variant is protein coding (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_014813.1">NM_014813.1</ext-link>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="urofacial" object-id="urofacial.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Benign allelic variants.</bold> Many nucleotide variants recognized in this gene are considered to be non-pathogenic.</p>
            <p><bold>Pathogenic allelic variants.</bold> To date few pathogenic changes that are presumed to be loss-of-function have been identified; they include frameshift and nonsense variants and a large Alu insertion [<xref ref-type="bibr" rid="urofacial.REF.stuart.2013.259">Stuart et al 2013</xref>].</p>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">LRIG2</italic> encodes the 1065-amino acid protein leucine-rich repeats and immunoglobulin-like domains protein 2 (LRIG2) [<xref ref-type="bibr" rid="urofacial.REF.holmlund.2004.35">Holmlund et al 2004</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_055628.1">NP_055628.1</ext-link>). LRIG2 shows about 50% identity to the homologs LRIG 1 and 3 [<xref ref-type="bibr" rid="urofacial.REF.guo.2004.157">Guo et al 2004</xref>]. The family has a common domain structure of a signal peptide, 15 tandem leucine-rich repeats (LRR) with cysteine-rich N- and C-flanking domains, three immunoglobulin-like (Ig-like) domains, a transmembrane domain, and a cytoplasmic tail [<xref ref-type="bibr" rid="urofacial.REF.nilsson.2001.1155">Nilsson et al 2001</xref>, <xref ref-type="bibr" rid="urofacial.REF.guo.2004.157">Guo et al 2004</xref>, <xref ref-type="bibr" rid="urofacial.REF.holmlund.2004.35">Holmlund et al 2004</xref>].</p>
            <p><bold>Abnormal gene product.</bold> The mechanism by which loss of LRIG2 results in disease is currently unknown.</p>
          </sec>
        </sec>
      </sec>
      <sec id="urofacial.References">
        <title>References</title>
        <sec id="urofacial.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="urofacial.Literature_Cited.reflist0">
            <ref id="urofacial.REF.akl.2012.346">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Akl</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Momany</surname>
                    <given-names>HM</given-names>
                  </name>
                </person-group>
                <article-title>Urofacial syndrome.</article-title>
                <source>Saudi J Kidney Dis Transpl.</source>
                <year>2012</year>
                <volume>23</volume>
                <fpage>346</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22382233</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.al_badr.2011.569">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al Badr</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Bader</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hildebrandt</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackley</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peng</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owens</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bloom</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Innis</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <article-title>Exome capture and massively parallel sequencing identifies a novel HPSE2 mutation in a Saudi Arabian child with Ochoa (urofacial) syndrome.</article-title>
                <source>J Pediatr Urol.</source>
                <year>2011</year>
                <volume>7</volume>
                <fpage>569</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">21450525</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.alqahtani.2003.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Qahtani</surname>
                    <given-names>FN</given-names>
                  </name>
                </person-group>
                <article-title>Ochoa syndrome: new features.</article-title>
                <source>Saudi J Kidney Dis Transpl.</source>
                <year>2003</year>
                <volume>14</volume>
                <fpage>61</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17657091</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.aydogdu.2010.431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aydogdu</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demirel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soygur</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozcakar</surname>
                    <given-names>ZB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yalcinkaya</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tekgul</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Ochoa syndrome: a spectrum of urofacial syndrome.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2010</year>
                <volume>169</volume>
                <fpage>431</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19669792</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.bacchetta.2010.225">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bacchetta</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochat</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Severe voiding dysfunction: ask the child to smile.</article-title>
                <source>Kidney Int.</source>
                <year>2010</year>
                <volume>78</volume>
                <fpage>225</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20588289</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.chauve.2000.10">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chauve</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Missirian</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malzac</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girardot</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guys</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Louis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philip</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voelckel</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Genetic homogeneity of the urofacial (Ochoa) syndrome confirmed in a new French family.</article-title>
                <source>Am J Med Genet.</source>
                <year>2000</year>
                <volume>95</volume>
                <fpage>10</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">11074487</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.cui.2011.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shao</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>K.</given-names>
                  </name>
                </person-group>
                <article-title>Heparanase enhances nerve-growth-factor-induced PC12 cell neuritogenesis via the p38 MAPK pathway.</article-title>
                <source>Biochem J.</source>
                <year>2011</year>
                <volume>440</volume>
                <fpage>273</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">21831044</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.daly.2010.963">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urquhart</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenzie</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kammerer</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerr</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuart</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnai</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Long</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aydogdu</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Derbent</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Minaur</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reardon</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gener</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shalev</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolf</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in HPSE2 cause urofacial syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2010</year>
                <volume>86</volume>
                <fpage>963</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20560210</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.derbent.2009.589">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Derbent</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>U&#x000e7;kan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baskin</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>Urofacial (ochoa) syndrome: can a facial gestalt represent severe voiding dysfunction?</article-title>
                <source>Ren Fail.</source>
                <year>2009</year>
                <volume>31</volume>
                <fpage>589</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">19839856</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.elejalde.1979.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elejalde</surname>
                    <given-names>BR</given-names>
                  </name>
                </person-group>
                <article-title>Genetic and diagnostic considerations in three families with abnormalities of facial expression and congenital urinary obstruction: "The Ochoa syndrome</article-title>
                <source>Am J Med Genet.</source>
                <year>1979</year>
                <volume>3</volume>
                <fpage>97</fpage>
                <lpage>108</lpage>
                <pub-id pub-id-type="pmid">474623</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.feldman.2006.139">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feldman</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>SB</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis and management of dysfunctional voiding.</article-title>
                <source>Curr Opin Pediatr.</source>
                <year>2006</year>
                <volume>18</volume>
                <fpage>139</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">16601493</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.fux.2009.511">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fux</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanderson</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlodavsky</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Heparanase: busy at the cell surface.</article-title>
                <source>Trends Biochem Sci.</source>
                <year>2009</year>
                <volume>34</volume>
                <fpage>511</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19733083</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.ganesan.2011.507">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganesan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>More than meets the smile: facial muscle expression in children with Ochoa syndrome.</article-title>
                <source>Med J Malaysia.</source>
                <year>2011</year>
                <volume>66</volume>
                <fpage>507</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22390114</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.garciaminaur.2001.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garcia-Minaur</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliver</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soriano</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinn</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reardon</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Three new European cases of urofacial (Ochoa) syndrome.</article-title>
                <source>Clin Dysmorphol.</source>
                <year>2001</year>
                <volume>10</volume>
                <fpage>165</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">11446407</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.guo.2004.157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmlund</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henriksson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedman</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea.</article-title>
                <source>Genomics.</source>
                <year>2004</year>
                <volume>84</volume>
                <fpage>157</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">15203213</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.hedman.2007.676">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hedman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henriksson</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?</article-title>
                <source>Eur J Cancer.</source>
                <year>2007</year>
                <volume>43</volume>
                <fpage>676</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">17239582</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.holmlund.2004.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmlund</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nilsson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Starefeldt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golovleva</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henriksson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedman</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Characterization and tissue-specific expression of human LRIG2.</article-title>
                <source>Gene.</source>
                <year>2004</year>
                <volume>332</volume>
                <fpage>35</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">15145052</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.homma.2009.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Homma</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hikake</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaginuma</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Expression pattern of LRR and Ig domain-containing protein (LRRIG protein) in the early mouse embryo.</article-title>
                <source>Gene Expr Patterns.</source>
                <year>2009</year>
                <volume>9</volume>
                <fpage>1</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">18848646</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.levyadam.2010.28010">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Levy-Adam</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feld</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen-Kaplan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shteingauz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arvatz</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naroditsky</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doweck</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlodavsky</surname>
                    <given-names>I.</given-names>
                  </name>
                </person-group>
                <article-title>Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity.</article-title>
                <source>J Biol Chem.</source>
                <year>2010</year>
                <volume>285</volume>
                <fpage>28010</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20576607</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.mahmood.2012.88">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mahmood</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beetz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tahir</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mumtaz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bassmann</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jahic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000fc;rnberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hassan</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rana</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000fc;rnberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000fc;bner</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>First HPSE2 missense mutation in urofacial syndrome.</article-title>
                <source>Clin Genet.</source>
                <year>2012</year>
                <volume>81</volume>
                <fpage>88</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">21332471</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.mckenzie.2000.1170">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McKenzie</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stamps</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barry</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hircock</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barry</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stubberfield</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terrett</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Page</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member.</article-title>
                <source>Biochem Biophys Res Commun.</source>
                <year>2000</year>
                <volume>276</volume>
                <fpage>1170</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11027606</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.nicanor.2005.477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nicanor</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pippi-Salle</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Early diagnosis of the urofacial syndrome is essential to prevent irreversible renal failure.</article-title>
                <source>Int Braz J Urol.</source>
                <year>2005</year>
                <volume>31</volume>
                <fpage>477</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">16255797</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.nilsson.2001.1155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nilsson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallbo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golovleva</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallberg</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henriksson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedman</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Cloning, characterization, and expression of human LIG1.</article-title>
                <source>Biochem Biophys Res Commun.</source>
                <year>2001</year>
                <volume>284</volume>
                <fpage>1155</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">11414704</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.ochoa.1987.661">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ochoa</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorlin</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Urofacial (ochoa) syndrome.</article-title>
                <source>Am J Med Genet.</source>
                <year>1987</year>
                <volume>27</volume>
                <fpage>661</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3631137</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.ochoa.2004.6">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ochoa</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Can a congenital dysfunctional bladder be diagnosed from a smile? The Ochoa syndrome updated.</article-title>
                <source>Pediatr Nephrol.</source>
                <year>2004</year>
                <volume>19</volume>
                <fpage>6</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">14648341</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.ochoa.1992.580">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ochoa</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>The urofacial (Ochoa) syndrome revisited.</article-title>
                <source>J Urol.</source>
                <year>1992</year>
                <volume>148</volume>
                <fpage>580</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">1640526</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.pang.2010.957">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins-Lee</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhong</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochoa</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agundez</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voelckel</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiong</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mei</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>She</surname>
                    <given-names>JX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>CY</given-names>
                  </name>
                </person-group>
                <article-title>Loss-of-function mutations in HPSE2 cause the autosomal recessive urofacial syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2010</year>
                <volume>86</volume>
                <fpage>957</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">20560209</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.sk_lov_.2006.125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sk&#x000e1;lov&#x000e1;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rejtar</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nov&#x000e1;k</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000fc;ttnerov&#x000e1;</surname>
                    <given-names>V.</given-names>
                  </name>
                </person-group>
                <article-title>The urofacial (Ochoa) syndrome--first case in the central European population.</article-title>
                <source>Prague Med Rep.</source>
                <year>2006</year>
                <volume>107</volume>
                <fpage>125</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16752812</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.stamatiou.2010.582">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stamatiou</surname>
                    <given-names>KN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karakos</surname>
                    <given-names>CD</given-names>
                  </name>
                </person-group>
                <article-title>Urofacial syndrome: A subset of neurogenic bladder dysfunction syndromes?</article-title>
                <source>Indian J Urol.</source>
                <year>2010</year>
                <volume>26</volume>
                <fpage>582</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21369396</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.stuart.2013.259">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stuart</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urquhart</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhaskar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dickerson</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mermerkaya</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silay</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olondriz</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gener</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beetz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varga</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;lp&#x00131;nar</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000fc;er</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soyg&#x000fc;r</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oz&#x000e7;akar</surname>
                    <given-names>ZB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yal&#x000e7;&#x00131;nkaya</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kavaz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bulum</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;c&#x000fc;k</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yue</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdogan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanley</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenzie</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton</surname>
                    <given-names>EN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolf</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <article-title>LRIG2 mutations cause urofacial syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>92</volume>
                <fpage>259</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">23313374</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.sutay.2010.445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sutay</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulkarni</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arya</surname>
                    <given-names>MK</given-names>
                  </name>
                </person-group>
                <article-title>Ochoa or Urofacial syndrome.</article-title>
                <source>Indian Pediatr.</source>
                <year>2010</year>
                <volume>47</volume>
                <fpage>445</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20519791</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.teebi.1991.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Teebi</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hassoon</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>Urofacial syndrome associated with hydrocephalus due to aqueductal stenosis.</article-title>
                <source>Am J Med Genet.</source>
                <year>1991</year>
                <volume>40</volume>
                <fpage>199</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">1897575</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.woolf.2014a.353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Woolf</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuart</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <article-title>Genetics of human congenital urinary bladder disease.</article-title>
                <source>Pediatr Nephrol.</source>
                <year>2014a</year>
                <volume>29</volume>
                <fpage>353</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">23584850</pub-id>
              </element-citation>
            </ref>
            <ref id="urofacial.REF.woolf.2014b.513">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Woolf</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuart</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenzie</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton</surname>
                    <given-names>EN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <article-title>Urofacial syndrome: a genetic and congenital disease of aberrant urinary bladder innervation.</article-title>
                <source>Pediatr Nephrol.</source>
                <year>2014b</year>
                <volume>29</volume>
                <fpage>513</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23832138</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="urofacial.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="urofacial.Author_Notes">
          <title>Author Notes</title>
          <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.human-development.manchester.ac.uk/staff/BillNewman">Bill Newman</ext-link> is a clinical geneticist with a research program that includes the identification of the causes of rare inherited disorders and subsequent development of targeted treatments.</p>
          <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.human-development.manchester.ac.uk/staff/AdrianWoolf/">Adrian S. Woolf</ext-link> is a clinician scientist and nephrologist. His research interest is to find out why some children are born with abnormal renal tracts.</p>
          <p>Helen M. Stuart is a Wellcome Trust Clinical Research Training Fellow and trainee in Clinical Genetics.</p>
        </sec>
        <sec id="urofacial.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The authors&#x02019; work on UFS has been funded by Kidney Research UK and the Wellcome Trust.</p>
        </sec>
        <sec id="urofacial.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>22 August 2013 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>17 May 2013 (wgn) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
